Fluoxetine during pregnancy: Impact on fetal development

Reproduction, Fertility and Development

Volumn 17, Issue 6, 2005, Pages 641-650

  Morrison, Janna L ^a   Riggs, K Wayne ^b   Rurak, Dan W ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; HYDROCORTISONE; MELATONIN; PAROXETINE; PROLACTIN; SEROTONIN; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL MODEL; BODY WEIGHT DISORDER; CARDIOVASCULAR FUNCTION; CIRCADIAN RHYTHM; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; FETUS DEVELOPMENT; FETUS MOVEMENT; HIGH RISK POPULATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS FUNCTION DISORDER; INTRAUTERINE GROWTH RETARDATION; LONG TERM CARE; NONHUMAN; PREGNANCY; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRESCRIPTION; REM SLEEP; REVIEW; SEROTONIN BLOOD LEVEL; SIDE EFFECT; SINGLE DRUG DOSE; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; UTERUS BLOOD FLOW; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CIRCADIAN RHYTHM; DEPRESSION; DISEASE MODELS, ANIMAL; FEMALE; FETAL DEVELOPMENT; FLUOXETINE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY-ADRENAL SYSTEM; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS; SHEEP; TERATOGENS;

ANIMALIA; OVIS ARIES;

EID: 25844526295     PISSN: 10313613     EISSN: None     Source Type: Journal    
DOI: 10.1071/RD05030     Document Type: Review

References (121)

1. Addis, A., and Koren, G. (2000). Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol. Med. 30, 89-94. doi: 10.1017/S0033291799001270
2. Alvarez, J. C., Gluck, N., Arnulf, I., Quintin, P., Leboyer, M., Pecquery, R., Launay, J. M., Perez-Diaz, F., and Spreux-Varoquaux, O. (1999a). Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin. Pharmacol. Ther. 66, 617-624.
3. Alvarez, J. C., Sanceaume, M., Advenier, C., and Spreux-Varoquaux, O. (1999b). Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice. Eur. Neuropsychopharmacol. 10, 31-36. doi: 10.1016/S0924-977X(99)00048-6
4. Andersson, L., Sundstrom-Poromaa, I., Wulff, M., Astrom, M., and Bixo, M. (2004a). Implications of antenatal depression and anxiety for obstetric outcome. Obstet. Gynecol. 104, 467-476.
5. Andersson, L., Sundstrom-Poromaa, I., Wulff, M., Astrom, M., and Bixo, M. (2004b). Neonatal outcome following maternal antenatal depression and anxiety: a population-based study. Am. J. Epidemiol. 159, 872-881. doi: 10.1093/AJE/KWH122
6. Arnon, J., Shechtman, S., and Ornoy, A. (2000). The use of psychiatric drugs in pregnancy and lactation. Israel J. Psychiat. 37, 205-222.
7. Begg, E. J., Duffull, S. B., Saunders, D. A., Buttimore, R. C., Ilett, K. F., Hackett, L. P., Yapp, P., and Wilson, D. A. (1999). Paroxetine in human milk. Br. J. Clin. Pharmacol. 48, 142-147. doi: 10.1046/J.1365-2125.1999.00992.X
8. Benfield, P., Heel, R. C., and Lewis, S. P. (1986). Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32, 481-508.
9. Boddy, K., Dawes, G. S., Fisher, R., Pinter, S., and Robinson, J. S. (1974). Foetal respiratory movements, electrocortical and cardiovascular responses to hypoxaemia and hypercapnia in sheep. J. Physiol. 243, 599-618.
10. Boland, R., Joyce, B. J., Wallace, M. J., Stanton, H., Fosang, A. J., Pierce, R. A., Harding, R., and Hooper, S. B. (2004). Cortisol enhances structural maturation of the hypoplastic fetal lung in sheep. J. Physiol. 554, 505-517. doi: 10.1113/JPHYSIOL.2003.055111
11. Byrd, R. A., and Markham, J. K. (1994). Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fund. Appl. Toxicol. 22, 511-518. doi: 10.1006/FAAT.1994.1058
12. Calvo, G., Garcia-Gea, C., Luque, A., Morte, A., Dal-Re, R., and Barbanoj, M. (2004). Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. J. Clin. Psychopharmacol. 24, 268-276. doi: 10.1097/01.JCP.0000125689.05091.C6
13. Casper, R. C., Fleisher, B. E., Lee-Ancajas, J. C., Gilles, A., Gaylor, E., DeBattista, A., and Hoyme, H. E. (2003). Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142, 402-408. doi: 10.1067/MPD.2003.139
14. Catterson, M. L., and Preskorn, S. H. (1996). Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol. Toxicol. 78, 203-208.
15. Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., and Jones, K. L. (1996). Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 335, 1010-1015. doi: 10.1056/NEJM199610033351402
16. Chambers, C. D., Anderson, P. O., Thomas, R. G., Dick, L. M., Felix, R. J., Johnson, K. A., and Jones, K. L. (1999). Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 104, 61-66. doi: 10.1542/PEDS.104.5.E61
17. Chien, C., Morrison, J. L., Gruber, N., Rurak, D., and Riggs, K. W. (1999). Chronic exposure and pharmacokinetics of fluoxetine and norfluoxetine enantiomers in the pregnant ewe and fetus. AAPS PharmSci. 1, S224.
18. Clapp, J. F., 3rd, Szeto, H. H., Abrams, R., Larrow, R., and Mann, L. I. (1980). Physiologic variability and fetal electrocortical activity. Am. J. Obstet. Gynecol. 136, 1045-1050.
19. Clark, K. E., Mills, E. G., Otte, T. E., and Stys, S. J. (1980). Effect of serotonin on uterine blood flow in pregnant and nonpregnant sheep. Life Sci. 27, 2655-2661. doi: 10.1016/0024-3205(80)90556-1
20. Cogill, S. R., Caplan, H. L., Alexandra, H., Robson, K. M., and Kumar, R. (1986). Impact of maternal postnatal depression on cognitive development of young children. Br. Med. J. (Clin. Res. Ed.) 292, 1165-1167.
21. Cohen, L. S., and Rosenbaum, J. F. (1997). Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 336, 872-873. doi: 10.1056/NEJM199703203361211
22. Cohen, L. S., Heller, V. L., Bailey, J. W., Grush, L., Ablon, J. S., and Bouffard, S. M. (2000). Birth outcomes following prenatal exposure to fluoxetine. Biol. Psychiatry 48, 996-1000. doi: 10.1016/S0006-3223(00)00877-5
23. Condon, J. T., and Corkindale, C. (1997). The correlates of antenatal attachment in pregnant women. Br. J. Med. Psychol. 70, 359-372.
24. Costei, A. M., Kozer, E., Ho, T., Ito, S., and Koren, G. (2002). Perinatal outcome following third trimester exposure to paroxetine. Arch. Pediatr. Adolesc. Med. 156, 1129-1132.
25. DeVane, C. L. (1999). Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. Mol. Neurobiol. 19, 443-466. doi: 10.1023/A:1006934807375
26. DiPietro, J. A., Costigan, K. A., and Pressman, E. K. (2002). Fetal state concordance predicts infant state regulation. Early Hum. Dev. 68, 1-13. doi: 10.1016/S0378-3782(02)00006-3
27. Dole, N., Savitz, D. A., Hertz-Picciotto, I., Siega-Riz, A. M., McMahon, M. J., and Buekens, P. (2003). Maternal stress and preterm birth. Am. J. Epidemiol. 157, 14-24. doi: 10.1093/AJE /KWF176
28. Edwards, L. J., and McMillen, I. C. (2002). Impact of maternal under-nutrition during the periconceptional period, fetal number, and fetal sex on the development of the hypothalamo-pituitary-adrenal axis in sheep during late gestation. Biol. Reprod. 66, 1562-1569.
29. Emslie, G., and Judge, R. (2000). Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr. Scand. Suppl. 403, 26-34.
30. Ener, R. A., Meglathery, S. B., Van Decker, W A., and Gallagher, R. M. (2003). Serotonin syndrome and other serotonergic disorders. Pain Med. 4, 63-74. doi: 10.1046/J.1526-4637.2003.03005.X
31. Epperson, N., Jatlow, P. I., Czarkowski, K., and Anderson, G. M. (2003). Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. Pediatrics 112, 425-429. doi: 10.1542/PEDS.112.5.E425
32. Ericson, A., Kallen, B., and Wiholm, B. (1999). Delivery outcome after the use of antidepressants in early pregnancy. Eur. J. Clin. Pharmacol. 55, 503-508. doi: 10.1007/S002280050664
33. Fletcher, D. J., Hanson, M. A., Moore, P. J., Nijhuis, J. G., and Parkes, M. J. (1988). Stimulation of breathing movements by L-5-hydroxytryptophan in fetal sheep during normoxia and hypoxia. J. Physiol. 404, 575-589.
34. Giussani, D. A., Fletcher, A. J. W., Fowden, A. L., and Gardner, D. S. (200 1). Ovine fetal cardiovascular, metabolic and endocrine response to hypoxaemia: difference between male and female fetuses. In '28th Annual Meeting of the Fetal and Neonatal Physiological Society, Auckland, New Zealand'. p. 102. (Fetal and Neonatal Physiological Society.)
35. Goldstein, D. J. (1995). Effects of third trimester fluoxetine exposure on the newborn. J. Clin. Psychopharmacol. 15, 417-420. doi: 10.1097/00004714-199512000-00005
36. Goldstein, D. J., Sundell, K. L., and Corbin, L. A. (1997). Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 336, 872-873.
37. Gupta, S., Banfield, C., Kantesaria, B., Flannery, B., and Herron, J. (2004). Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J. Clin. Pharmacol. 44, 1252-1259. doi: 10.1177/0091270004269518
38. Heikkinen, T., Ekblad, U., Palo, P., and Lame, K. (2003). Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin. Pharmacol. Ther. 73, 330-337. doi: 10.1016/S0009-9236(02)17634-X
39. Hendrick, V., Smith, L. M., Hwang, S., Altshuler, L. L., and Haynes, D. (2003a). Weight gain in breastfed infants of mothers taking antidepressant medications. J. Clin. Psychiatry 64, 410-412.
40. Hendrick, V., Smith, L. M., Suri, R., Hwang, S., Haynes, D., and Altshuler, L. (2003b). Birth outcomes after prenatal exposure to antidepressant medication. Am. J. Obstet. Gynecol. 188, 812-815. doi: 10.1067/MOB.2003.172
41. Hendrick, V., Stowe, Z. N., Altshuler, L. L., Hwang, S., Lee, E., Haynes, D., Heikkinen, T., Ekblad, U., Palo, P., and Laine, K. (2003c). Placental passage of antidepressant medications: pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Am. J. Psychiatry 160, 993-996. doi: 10.1176/APPI.AJP.160.5.993
42. Hiemke, C., and Hartter, S. (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 85, 11-28. doi: 10.1016/S0163-7258(99)00048-0
43. Hoffman, S., and Hatch, M. C. (1996). Stress, social support and pregnancy outcome: a reassessment based on recent research. Paediatr. Perinat. Epidemiol. 10, 380-405.
44. Isbister, G. K., Dawson, A., Whyte, I. M., Prior, F. H., Clancy, C., and Smith, A. J. (2001). Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch. Dis. Child. Fetal Neonatal Ed. 85, F147-F148.
45. Kallen, B. (2004). Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 158, 312-316. doi: 10.1001/ARCHPEDI.158.4.312
46. Kent, L. S., and Laidlaw, J. D. (1995). Suspected congenital sertraline dependence. Br. J. Psychiatry 167, 412-413.
47. Kessler, R. C., McGonagle, K. A., Swartz, M., Blazer, D. G., and Nelson, C. B. (1993). Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J. Affect. Disord. 29, 85-96. doi: 10.1016/0165-0327(93)90026-G
48. Kim, J., Axelson, J. E., Kearns, G. L., Yin, W., and Rurak, D. (1995). Stereoselcetive determination of fluoxetine and norfluxoetine with mass-selective detection (GC/MSD). Pharm. Res. 12, s22.
49. Kim, J., Riggs, K. W., and Rurak, D. W. (2004). Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. Drug Metab. Dispos. 32, 212-221. doi: 10.1124/DMD.32.2.212
50. Koren, G. (2002). SSRIs in pregnancy: are they safe? Pediatr. Res. 51, 424-425.
51. Koren, G. (2004). Discontinuation syndrome following late pregnancy exposure to antidepressants. Arch. Pediatr. Adolesc. Med. 158, 307-308. doi: 10.1001/ARCHPEDI.158.4.307
52. Koren, G., Nulman, I., and Addis, A. (1998). Outcome of children exposed in utero to fluoxetine: a critical review. Depress. Anxiety 8(Suppl. 1), 27-31. doi: 10.1002/(SICI)1520-6394(1998)8:1+<27::AID-DA5>3.0.CO;2-K
53. Kotzailias, N., Marker, M., and Jilma, B. (2004). Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 24, 536-539. doi: 10.1097/01.JCP.0000138765.08235.46
54. Kristensen, J. H., Ilett, K. F., Dusci, L. J., Hackett, L. P., Yapp, P., Wojnar-Horton, R. E., Roberts, M. J., and Paech, M. (1998). Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br. J. Clin. Pharmacol. 45, 453-457. doi: 10.1046/J.1365-2125.1998.00705.X
55. Kristensen, J. H., Ilett, K. F., Hackett, L. P., Yapp, P., Paech, M., and Begg, E. J. (1999). Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br. J. Clin. Pharmacol. 48, 521-527. doi: 10.1046/J.1365-2125.1999.00040.X
56. Lame, K., Heikkinen, T., Ekblad, U., and Kero, P. (2003). Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60, 720-726. doi: 10.1001/ARCHPSYC.60.7.720
57. Larsson, C., Sydsjo, G., and Josefsson, A. (2004). Health, sociodemographic data, and pregnancy outcome in women with antepartum depressive symptoms. Obstet. Gynecol. 104, 459-466.
58. Lawrenson, R. A., Tyrer, F., Newson, R. B., and Farmer, R. D. (2000). The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J. Affect. Disord. 59, 149-157. doi: 10.1016/S0165-0327(99)00147-0
59. Ledward, R. S. (1996). Drugs in pregnancy. Prog. Obstet. Gynecol. 12, 19-46.
60. Marcus, S. M., Flynn, H. A., Blow, F. C., and Barry, K. L. (2003). Depressive symptoms among pregnant women screened in obstetrics settings. J. Womens Health 12, 373-380.
61. Martin, J. A., Hamilton, B. E., Ventura, S. J., Menacker, F., Park, M. M., and Sutton, P. D. (2002). Births: final data for 2001. Natl Vital Stat. Rep. 51, 1-102.
62. McCormick, M. C., Brooks-Gunn, J., Shorter, T., Holmes, J. H., Wallace, C. Y., and Heagarty, M. C. (1990). Factors associated with smoking in low-income pregnant women: relationship to birth weight, stressful life events, social support, health behaviors and mental distress. J. Clin. Epidemiol. 43, 441-448. doi: 10.1016/0895-4356(90)90132-9
63. McElhatton, P. R., Garbis, H. M., Elefant, E., Vial, T., Bellemin, B., et al. (1996). The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod. Toxicol. 10, 285-294. doi: 10.1016 /0890-6238(96)00057-3
64. McIntosh, G. H., Baghurst, K. I., Potter, B. J., and Hetzel, B. S. (1979). Foetal brain development in the sheep. Neuropathol. Appl. Neurobiol. 5, 103-114.
65. Morin, L. P. (1999). Serotonin and the regulation of mammalian circadian rhythmicity. Ann. Med. 31, 12-33.
66. Morrison, J. L., Carmichael, L., Homan, J., and Richardson, B. S. (1997). The effects of 'sleep promoting agents' on behavioural state in the ovine fetus. Brain Res. Dev. Brain Res. 103, 1-8. doi: 10.1016/S0165-3806(97)00093-X
67. Morrison, J. L., Chien, C., Gruber, N., Rurak, D., and Riggs, W. (2001). Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Dev. Brain Res. 131, 47-56. doi: 10.1016/S0165-3806(01)00255-3
68. Morrison, J. L., Chien, C., Riggs, K. W., Gruber, N., and Rurak, D. (2002). Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth. Pediatr. Res. 51, 433-442.
69. Morrison, J. L., Riggs, K. W., Chien, C., Gruber, N., McMillen, I. C., and Rurak, D. W. (2004). Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes. Pediatr. Res. 56, 40-46. doi: 10.1203/01.PDR.0000128981.38670.28
70. Morrison, J. L., Rurak, D., Chien, C., Kennaway, D. J., Gruber, N., McMillen, I. C., and Riggs, K. W. (2005). Maternal fluoxetine infusion does not alter fetal endocrine and biophysical circadian rhythms in pregnant sheep. J. Soc. Gynecol. Investig. 12, 356-364.
71. Mourilhe, P., and Stokes, P. E. (1998). Risks and benefits of selective scrotonin reuptake inhibitors in the treatment of depression. Drug Saf. 18, 57-82.
72. Newnham, J. P., Moss, T. J., Nitsos, I., and Sloboda, D. M. (2002). Antenatal corticosteroids: the good, the bad and the unknown. Curr. Opin. Obstet. Gynecol. 14, 607-612. doi: 10.1097/00001703-200212000-00006
73. Noble, R. E. (2005). Depression in women. Metabolism 54, 49-52. doi: 10.1016/J.METABOL.2005.01.014
74. Nordeng, H., Lindemann, R., Perminov, K. V., and Reikvam, A. (2001). Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 90, 288-291. doi: 10.1080/080352501300067596
75. Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., Theis, J. G., Kulin, N., and Koren, G. (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336, 258-262. doi: 10.1056/NEJM199701233360404
76. Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Pace-Asciak, P., Shuhaiber, S., and Koren, G. (2002). Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry 159, 1889-1895. doi: 10.1176/APPI.AJP.159.11.1889
77. Oberlander, T. F., Grunau, R. E., Fitzgerald, C., Ellwood, E. L., Misri, S., Rurak, D., and Riggs, K. W. (2002). Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr. Res. 51, 443-453.
78. Oberlander, T. F., Grunau, R. E., Fitzgerald, C., Papsdorf, M., Rurak, D., and Riggs, W. (2005). Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115, 411-425. doi: 10.1542/PEDS.2004-0420
79. O'Hara, M. W., Neunaber, D. J., and Zekoski, E. M. (1984). Prospective study of postpartum depression: prevalence, course, and predictive factors. J. Abnorm. Psychol. 93, 158-171. doi: 10.1037//0021-843X.93.2.158
80. Orr, S. T., and Miller, C. A. (1995). Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol. Rev. 17, 165-171.
81. Orr, S. T., James, S. A., and Blackmore Prince, C. (2002). Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am. J. Epidemiol. 156, 797-802. doi: 10.1093/AJE/KWF131
82. Ortiz, J., and Artigas, F. (1992). Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br. J. Pharmacol. 105, 941-946.
83. Palmer, S. K., Zamudio, S., Coffin, C., Parker, S., Stamm, E., and Moore, L. G. (1992). Quantitative estimation of human uterine artery blood flow and pelvic blood flow redistribution in pregnancy. Obstet. Gynecol. 80, 1000-1006.
84. Pastuszak, A., Schick-Boschetto, B., Zuber, C., Feldkamp, M., Pinelli, M., et al. (1993). Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269, 2246-2248. doi: 10.1001/JAMA.269.17.2246
85. Peacock, J. L., Bland, J. M., and Anderson, H. R. (1995). Preterm delivery: effects of socioeconomic factors, psychological stress, smoking, alcohol, and caffeine. BMJ 311, 531-535.
86. Philipps, L. H., and O'Hara, M. W. (1991). Prospective study of postpartum depression: 41/2-year follow-up of women and children. J. Abnorm. Psychol. 100, 151-155. doi: 10.1037//0021-843X.100.2.151
87. Pillai, M., and James, D. (1990). Development of human fetal behavior: a review. Fetal Diagn. Ther. 5, 15-32.
88. Prosser, R. A. (2000). Serotonergic actions and interactions on the SCN circadian pacemaker: in vitro investigations. Biol. Rhythm Res. 31, 315-339. doi: 10.1076/0929-1016(200007)31:3;1-K;FT315
89. Quilligan, E. J., Clewlow, F., Johnston, B. M., and Walker, D. W. (1981). Effect of 5-hydroxytryptophan on electrocortical activity and breathing movements of fetal sheep. Am. J. Obstet. Gynecol. 141, 271-275.
90. Rampono, J., Kristensen, J. H., Hackett, L. P., Paech, M., Kohan, R., and Ilett, K. F. (2000). Citalopram and demethylcitalopram in human milk: distribution, excretion and effects in breast fed infants. Br. J. Clin. Pharmacol. 50, 263-268. doi: 10.1046/J.1365-2125.2000.00253.X
91. Rampono, J., Proud, S., Hackett, L. P., Kristensen, J. H., and Ilett, K. F. (2004). A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int. J. Neuropsychopharmacol. 7, 329-334. doi: 10.1017/S1461145704004286
92. Rementeria, J. L., and Bhatt, K. (1977). Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J. Pediatr. 90, 123-126.
93. Richardson, B. S. (1994). Ontogeny of behavioural states in the fetus. In 'Textbook of Fetal Physiology'. (Eds G. D. Thornburn and R. Harding.) pp. 322-328. (Oxford University Press: Oxford, UK.)
94. Robert, E. (1996). Treating depression in pregnancy. N. Engl. J. Med. 335, 1056-1058. doi: 10.1056/NEJM199610033351411
95. Roberts, C. L., and Lancaster, P. A. (1999). Australian national birth-weight percentiles by gestational age. Med. J. Aust. 170, 114-118.
96. Roffwarg, H. P., Muzio, J. N., and Dement, W. C. (1966). Ontogenetic development of the human sleep-dream cycle. Science 152, 604-619.
97. Rossi, A., Barraco, A., and Donda, P. (2004). Fluoxetine: a review on evidence based medicine. Ann. Gen. Hosp. Psychiatry 3, 2-9. doi: 10.1186/1475-2832-3-2
98. Sanz, E. J., De-las-Cuevas, C., Kiuru, A., Bate, A., and Edwards, R. (2005). Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365, 482-487.
99. Scharf, A., Seppelt, M., and Sohn, C. (2003). Doppler flow velocity to measure the redistribution of fetal cardiac output in fetal stress. Eur. J. Obstet. Gynecol. Reprod. Biol. 110, S119-S126. doi: 10.1016/S0301-2115(03)00182-9
100. Schwartz, J., and McMillen, I. C. (2001). Fetal hypothalamus-pituitary-adrenal axis on the road to parturition. Clin. Exp. Pharmacol. Physiol. 28, 108-112. doi: 10.1046/J.1440-1681.2001.03412.X
101. Shader, R. I. (1992a). Does continuous use of fluoxetine during the first trimester of pregnancy present a high risk for malformation or abnormal development to the exposed fetus? J. Clin. Psychopharmacol. 12, 441.
102. Shader, R. I. (1992b). A patient of mine missed a period while taking fluoxetine; it turned out that she was not pregnant. However, the question arose about the safety of fluoxetine during pregnancy. What is known? J. Clin. Psychopharmacol. 12, 213.
103. Silvestri, R., Pace-Schott, E. F., Gersh, T., Stickgold, R., Salzman, C., and Hobson, J. A. (2001). Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based nightcap evaluation during drug administration and withdrawal. J. Clin. Psychiatry 62, 642-652.
104. Simon, G. E., Cunningham, M. L., and Davis, R. L. (2002). Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry 159, 2055-2061. doi: 10.1176/APPI.AJP.159.12.2055
105. Speight, A. N. (1977). Floppy-infant syndrome and maternal diazepam and/or nitrazepam. Lancet 310, 878. doi: 10.1016/S0140-6736(77)90817-0
106. Spencer, M. J. (1993). Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 92, 721-722.
107. Stanford, M. S., and Patton, J. H. (1993). In utero exposure to fluoxetine HCl increases hematoma frequency at birth. Pharmacol. Biochem. Behav. 45, 959-962. doi: 10.1016/0091-3057(93)90147-L
108. Steer, R. A., Scholl, T. O., Hediger, M. L., and Fischer, R. L. (1992). Self-reported depression and negative pregnancy outcomes. J. Clin. Epidemiol. 45, 1093-1099. doi: 10.1016/0895-4356(92)90149-H
109. Stiskal, J. A., Kulin, N., Koren, G., Ho, T., and Ito, S. (2001). Neonatal paroxetine withdrawal syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 84, F134-F135. doi: 10.1136/FN.84.2.F134
110. Stokes, P. E., and Holtz, A. (1997). Fluoxetine tenth anniversary update: the progress continues. Clin. Ther. 19, 1135-1250. doi: 10.1016/S0149-2918(97)80066-5
111. Suri, R., Altshuler, L., Hendrick, V., Rasgon, N., Lee, E., and Mintz, J. (2004). The impact of depression and fluoxetine treatment on obstetrical outcome. Arch. Women Ment. Health 7, 193-200.
112. Tabor, B. L., Lewis, J. F., Ikegami, M., Polk, D., and Jobe, A. H. (1994). Corticosteroids and fetal intervention interact to alter lung maturation in preterm lambs. Pediatr. Res. 35, 479-483.
113. Thase, M. E. (1998). Depression, sleep, and antidepressants. J. Clin. Psychiatry 59, 55-65.
114. Ursin, R. (2002). Serotonin and sleep. Sleep Med. Rev. 6, 55-69. doi: 10.1053/SMRV.2001.0174
115. Vorhees, C. V., Acuff-Smith, K. D., Schilling, M. A., Fisher, J. E., Moran, M. S., and Buelke-Sam, J. (1994). A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam. Appl. Toxicol. 23, 194-205. doi: 10.1006/FAAT.1994.1098
116. Weissman, M. M., and Olfson, M. (1995). Depression in women: implications for health care research. Science 269, 799-801.
117. Wen, S. W., and Walker, M. (2004). The use of selective serotonin reuptake inhibitors in pregnancy. J. Obstet. Gynaecol. Can. 26, 819-822.
118. Wood, C. E. (1994). The function of the fetal pituitary-adrenal system. In 'Textbook of Fetal Physiology'. (Eds G. D. Thornburn and R. Harding.) pp. 351-358. (Oxford University Press: Oxford, UK.)
119. Yoshioka, T., Inomata, K., Sugioka, K., and Nakamura, K. (1980). Ultrastructural study on myelination in rat spinal cord during the early postnatal stage. Brain Dev. 2, 337-343.
120. Zemdegs, I. Z., McMillen, I. C., Walker, D. W., Thorburn, G. D., and Nowak, R. (1988). Diurnal rhythms in plasma melatonin concentrations in the fetal sheep and pregnant ewe during late gestation. Endocrinology 123, 284-289.
121. Zeskind, P. S., and Stephens, L. E. (2004). Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113, 368-375. doi: 10.1542/PEDS.113.2.368